PMID: 41545327

The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.

Ganamurali Nila, Sabarathinam Sarvesh

Clinical pharmacology in drug development · 2026

Vol. 15, Issue 1, pp. e70001

View on PubMedDOI

This entry links to third-party literature. For research use only.

HumansObesityGlucagon-Like Peptide-1 Receptor AgonistsGastric Inhibitory PolypeptideCardiovascular DiseasesAnti-Obesity AgentsGlucagon-Like Peptide 1ComorbidityAnimalsReceptors, Glucagon

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.